| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Docosahexaenoic acid ethyl ester does not have a defined pharmacological target. As a source of DHA, it is incorporated into cell membranes where it influences membrane fluidity and function. It can also serve as a precursor for bioactive lipid mediators, such as resolvins and protectins, which have anti-inflammatory and pro-resolving properties.
|
|---|---|
| ln Vitro |
In vitro, docosahexaenoic acid ethyl ester can be used to study the effects of DHA on cellular processes. DHA is known to modulate cell signaling, gene expression, and membrane properties. The compound can also induce lipid peroxidation due to its high content of double bonds.
|
| ln Vivo |
Twice daily for seven days, 500 mg/kg of docosahexaenoic acid ethyl ester (DHA-EE) intraperitoneally (i.p.) amplifies the 6-OHDA-induced decrease in striatal dopamine levels [2].
In vivo, docosahexaenoic acid ethyl ester increases plasma and erythrocyte membrane DHA levels. It supports cardiovascular health, reduces triglyceride levels, and contributes to normal brain and retinal function. Its bioactivity stems from its role in membrane fluidity, anti-inflammatory signaling, and neural development. |
| Enzyme Assay |
Non-cellular assays for docosahexaenoic acid ethyl ester involve measuring its effects on lipid membranes. The compound can be incorporated into liposomes or other model membranes to study its effects on membrane fluidity and permeability. Its susceptibility to oxidation can also be assessed in vitro.
|
| Cell Assay |
Cell-based assays for docosahexaenoic acid ethyl ester involve studying its effects on cells. Cells can be treated with the compound, and changes in membrane composition, cell signaling, gene expression, and inflammatory responses can be assessed. The compound's effects on neuronal cells and retinal cells are of particular interest.
|
| Animal Protocol |
In vivo animal experiments with docosahexaenoic acid ethyl ester involve administering the compound to animals to study its effects on various physiological parameters. Animal models of neurological disorders, cardiovascular disease, and metabolic syndrome can be used. The compound enhances 6-hydroxydopamine-induced neuronal damage by inducing lipid peroxidation in the mouse striatum.
|
| ADME/Pharmacokinetics |
Docosahexaenoic acid ethyl ester is absorbed following oral administration. It is hydrolyzed to DHA, which is then incorporated into cell membranes or metabolized. Its pharmacokinetic profile is similar to that of other omega-3 fatty acid ethyl esters.
|
| Toxicity/Toxicokinetics |
Docosahexaenoic acid ethyl ester is generally recognized as safe (GRAS) as a food ingredient. It is well-tolerated at recommended doses. High doses may cause gastrointestinal side effects.
|
| References |
[1]. Dahms I, et al. Safety of docosahexaenoic acid (DHA) administered as DHA ethyl ester in a 9-month toxicity study in dogs. Food Chem Toxicol. 2016;92:50-57.
[2]. Kabuto H, et al. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Neurochem Res. 2009;34(7):1299-1303. |
| Additional Infomation |
Ethyl docosahexaenoic acid (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid is a long-chain fatty acid ethyl ester formed by the condensation of the carboxyl group of (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoic acid with the hydroxyl group of ethanol. Functionally, it is associated with all-cis-docosahexaenoic acid (4,7,10,13,16,19-hexaenoic acid).
Docosahexaenoic acid ethyl ester is a dietary supplement and not an approved drug. It is used to support cardiovascular health, cognitive function, and retinal health. It is often incorporated into therapeutic products aimed at metabolic health and long-term wellness. |
| Molecular Formula |
C24H36O2
|
|---|---|
| Molecular Weight |
356.54
|
| Exact Mass |
355.264
|
| CAS # |
81926-94-5
|
| Related CAS # |
Docosahexaenoic acid ethyl ester-d5;2692624-15-8;Docosahexaenoic acid ethyl ester-d5-1;159146-01-7
|
| PubChem CID |
9831416
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.994
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
26
|
| Complexity |
490
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(/CCC(=O)OCC)=C/C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
|
| InChi Key |
ITNKVODZACVXDS-YNUSHXQLSA-N
|
| InChi Code |
InChI=1S/C24H36O2/c1-3-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24(25)26-4-2/h5-6,8-9,11-12,14-15,17-18,20-21H,3-4,7,10,13,16,19,22-23H2,1-2H3/b6-5-,9-8-,12-11-,15-14-,18-17-,21-20-
|
| Chemical Name |
ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (280.47 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.01 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (7.01 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8047 mL | 14.0237 mL | 28.0473 mL | |
| 5 mM | 0.5609 mL | 2.8047 mL | 5.6095 mL | |
| 10 mM | 0.2805 mL | 1.4024 mL | 2.8047 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
